Arcus Biosciences (RCUS)’ quemliclustat was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Advances Phase 1 Study for Promising Cancer Treatment
- Gilead and Arcus Biosciences’ Promising Oncology Study Update
- Arcus Biosciences’ AB598 Study: A New Frontier in Cancer Treatment
- Gilead and Arcus Advance Promising Colorectal Cancer Study
- Gilead and Arcus Advance Phase 2 Study in Lung Cancer Immunotherapy